Aim: to evaluate the performance of N-staging assessment in clinically-proven T1 breast carcinoma by high-resolution F-fluorodeoxyglucose-positron-emission tomography/computed tomography (F-FDG-PET/CT) using time-of-flight with point-spread function reconstruction.
Patients And Methods: In 30 women with clinically proven T1 breast carcinoma, imaging before surgery was performed using F-FDG-PET/CT. The results of PET/CT in detection of lymph node metastases were compared with those obtained after pathological investigation of axillary biopsy.
Background/aim: The results of surgical treatment of breast cancer liver metastases (BCLM) remain suboptimal. The search for perioperative prognostic factors could help determine high risk groups of patients. The aim of study was to evaluate the significance of tumour markers (TM) on long-term treatment results.
View Article and Find Full Text PDFAim: The aim of this study was to evaluate the ability of tissue polypeptide-specific antigen (TPS), carcinoembryonic antigen (CEA), and cancer antigen 15-3 (CA 15-3) to predict relapse in breast cancer patients, when the measurement of biomarkers is performed within 6 months after surgery.
Patients And Methods: Four hundred and seventy-two patients with breast cancer were evaluated. TPS, CEA, and CA 15-3 were measured in months 1, 3, and 6, after surgery.
Background/aim: The aim of this study was to evaluate experience with multiparametric breast imaging on 3-Tesla magnetic resonance (3T-MRI) scanner using a dedicated 18-channel coil compared to histological findings in women after surgery.
Materials And Methods: The study included 100 women with 105 Breast Imaging Reporting and Data System (BI-RADS) 4 to 6 lesions by mammography who were examined using 3T-MRI and subsequently underwent surgery. MRI included non-contrast T1, T2 and T2 short tau inversion recovery (STIR) sequences, diffusion-weighted imaging with apparent diffusion coeficient maps, postcontrast dynamic study and single-voxel MRI spectroscopy.
Introduction: Breast cancer is the most common malignant disease in women and represents a worldwide problem. Up-to-date diagnostics methods, mammography screening and complex treatments have resulted in a substantial reduction of mortality rates. However, the incidence of the disease keeps growing constantly, although in a moderate way.
View Article and Find Full Text PDF